Parkinson's Pipeline Assessment and Insights Report 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Parkinson's: Pipeline Assessment and Insights" report has been added to ResearchAndMarkets.com's offering.

Parkinson's: Pipeline Assessment and Insights report delivers an in-depth understanding of the disease, highlights all the pipeline products in different phases of development for the disease including the Suspended products and outlines in detail the drug profiles of key Pipeline therapies in the disease area.

Pipeline Covered:

  • NDA/BLA Filed
  • Phase III Pipeline
  • Phase II Pipeline
  • Phase I Pipeline
  • Preclinical Pipeline
  • Discovery Pipeline
  • Suspended and Terminated products
  • Pipeline analysis by Mechanism of Action
  • Pipeline Analysis by Novelty of Mechanism of Action

Key Topics Covered:

1 Tables & Figures

2 Parkinson's Disease

2.1 Disease Overview

2.1.1 Disease Definition

2.1.2 Disease Epidemiology

2.1.3 Current Treatment Options

2.1.4 Key unmet needs

3 Pipeline Assessment

3.1 Overview

3.2 Strategic Review of the Pipeline

3.3 Pipeline analysis by Phases of Development

3.3.1 NDA/BLA Filed

3.3.2 Phase III Pipeline

3.3.3 Phase II Pipeline

3.3.4 Phase I Pipeline

3.3.5 Preclinical Pipeline

3.3.6 Discovery Pipeline

3.4 Pipeline Analysis by Mechanism of Action

3.5 Pipeline Analysis by Novelty of Mechanism of Action

3.6 Suspended and Terminated products

3.7 Parkinson's - Promising Therapies in Pipeline

3.7.1 APL-130277

3.7.2 Inbrija

3.7.3 ND0612

3.7.4 EPI-589

3.7.5 PRX002

4 Appendix

Companies Mentioned

  • Bristol-Myers Squibb
  • Ligand Pharmaceuticals
  • Lundbeck
  • Otsuka Holdings
  • Abdi Ibrahim
  • Genovate Biotechnology
  • Eli Lilly
  • Elan
  • Johnson & Johnson
  • Alkermes
  • Merck & Co
  • Daiichi Sankyo
  • Takeda
  • Sumitomo Dainippon Pharma
  • Les Laboratoires Servier
  • Bukwang Pharmaceutical
  • Gruppo Angelini
  • Standard Chem. & Pharm.
  • NewBridge Pharmaceuticals
  • Forest Laboratories
  • Recordati
  • Mitsubishi Tanabe Pharma
  • Gedeon Richter
  • Allergan
  • Schering-Plough
  • Pfizer
  • Meiji Holdings
  • AstraZeneca
  • Mitsubishi Pharma
  • Cyrenaic Pharmaceuticals
  • Minerva Neurosciences
  • Intra-Cellular Therapies
  • ACADIA Pharmaceuticals
  • Ipsen
  • Astellas Pharma

For more information about this report visit https://www.researchandmarkets.com/research/5w467s/parkinsons?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs